Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000203813 | SCV000261973 | uncertain significance | Myofibrillar myopathy 6; Dilated cardiomyopathy 1HH | 2022-10-17 | criteria provided, single submitter | clinical testing | This variant has not been reported in the literature in individuals affected with BAG3-related conditions. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt BAG3 protein function. ClinVar contains an entry for this variant (Variation ID: 220969). This variant is present in population databases (rs369690617, gnomAD 0.002%). This sequence change replaces alanine, which is neutral and non-polar, with glycine, which is neutral and non-polar, at codon 529 of the BAG3 protein (p.Ala529Gly). |
Fulgent Genetics, |
RCV000203813 | SCV002786922 | uncertain significance | Myofibrillar myopathy 6; Dilated cardiomyopathy 1HH | 2021-07-27 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004992080 | SCV005543981 | uncertain significance | Cardiovascular phenotype | 2024-11-07 | criteria provided, single submitter | clinical testing | The c.1586C>G (p.A529G) alteration is located in exon 4 (coding exon 4) of the BAG3 gene. This alteration results from a C to G substitution at nucleotide position 1586, causing the alanine (A) at amino acid position 529 to be replaced by a glycine (G). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |